Targeting the Apelinergic signaling pathway to drive improved health outcomes
Therapeutic Drug Development Pipeline
Using the vast library of selective oral small molecules, APIE Therapeutics’ robust development program is targeting several primary indications.
Idiopathic Pulmonary Fibrosis (IPF)
Kidney Nephrotic Syndrome
Metabolic Syndrome (Liver Steatosis; Glucose Utilization; Weight Loss)
Covid19-Endothelium Organ Vascular Damage (prophylactic)
Pulmonary Dysplasia (BPD)
The Initial Challenge
APIE Therapeutics Apelin Receptor (APJ) Agonists Discovery Platform
APIE Therapeutics has a strong IP portfolio of several issued patents with broad supported claims covering many variations on the base scaffold including the lead compound of interest. These patents have long patent life remaining (2037 and beyond) and have been filed extensively internationally. The patent portfolio contains several family members with different structural classes and methods of use filed later to provide additional patent protection and term.